Market Overview:
The global bullous pemphigoid therapies market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of bullous pemphigoid, rising awareness about the disease, and technological advancements in the field of bullous pemphigoid therapies. However, high costs associated with treatment and lack of reimbursement are expected to restrain the growth of this market during the forecast period. The global bullous pemphigoid therapies market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into steroid creams, immune suppressants, and antibiotics. On the basis of application, it is segmented into initial phase therapy (treatment for newly diagnosed patients), active treatment phase (treatment for patients who are responding well to therapy), reducing phase (treatment for patients whose symptoms have improved after active treatment), and maintenance phase (treatment for patients who have achieved remission). The regional segments include North America, Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Bullous pemphigoid is a rare autoimmune blistering disease that most often affects adults older than 60. The disease causes large, fluid-filled blisters to form on the skin.
Steroid Creams:
Steroid creams are used for the treatment of bullous pemphigoid and skin rashes due to sensitivity to sunlight. It is also used in the treatment of atopic dermatitis, psoriasis, and sebostasis. The drug works by reducing inflammation caused by histamine produced during an allergic response.
Immune Suppressants:
Immune suppressants are drugs that act to reduce the immune response to a particular drug or antigen. They can be used in various therapeutic applications such as autoimmune diseases, transplantation, and cancer chemotherapy. The main function of these drugs is to decrease the inflammatory response by suppressing interleukin (IL) - 1, tumor necrosis factor (TNF), and other cytokines produced by activated immune cells.
Application Insights:
The initial phase of bullous pemphigoid treatment application segment dominated the market in 2017. This is due to the high incidence of bullous pemphigoid among patients in their initial phase. In addition, this treatment option is relatively more expensive as compared to other treatments such as steroids and immunosuppressants which are used for active and reducing phases, respectively.
The maintenance phase of bullous pemphigoid therapy is expected to witness lucrative growth over the forecast period owing to increasing awareness about its side effects and availability of various alternative therapies that reduce these side effects without causing any harm or discomfort towards patient.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives and increasing prevalence of bullous pemphigoid are some factors responsible for its large share. For instance, in November 2016, Fovista launched FOLOTYN (ciclosporin) patch test device to improve the existing treatment options for BP patients.
Asia Pacific is expected to be one of fastest growing regions over the forecast period owing to rising healthcare expenditure and improving access due to various government initiatives such as Make in India campaign by Indian Government and One Belt One Road Initiative (OBOR) by Chinese Government which will open up new markets across Asia Pacific region.
Growth Factors:
- Increasing incidence of bullous pemphigoid
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective therapies for bullous pemphigoid
- Availability of novel therapies and treatments that are helping to improve the prognosis of the disease
- Growing research and development activities in this area
Scope Of The Report
Report Attributes
Report Details
Report Title
Bullous Pemphigoid Therapies Market Research Report
By Type
Steroid Creams, Immune Suppressants, Antibiotics
By Application
Initial Phase, Active Treatment Phase, Reducing Phase, Maintenance Phase
By Companies
Regeneron Pharmaceuticals, Sanofi, Pfizer, SUANFARMA, Tecoland Corporation, Century Pharmaceuticals, Akari Therapeutics, Immune Pharmaceuticals, Innate Pharma, AstraZeneca, Grifols, Aptalis, Medicis Pharmaceutical Corporation, Shaanxi Xiyue Pharmaceutical, Kunming Zhenhua Pharmaceutical Factory, Qinghai Pharmaceutical Factory
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Bullous Pemphigoid Therapies Market Report Segments:
The global Bullous Pemphigoid Therapies market is segmented on the basis of:
Types
Steroid Creams, Immune Suppressants, Antibiotics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Initial Phase, Active Treatment Phase, Reducing Phase, Maintenance Phase
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Regeneron Pharmaceuticals
- Sanofi
- Pfizer
- SUANFARMA
- Tecoland Corporation
- Century Pharmaceuticals
- Akari Therapeutics
- Immune Pharmaceuticals
- Innate Pharma
- AstraZeneca
- Grifols
- Aptalis
- Medicis Pharmaceutical Corporation
- Shaanxi Xiyue Pharmaceutical
- Kunming Zhenhua Pharmaceutical Factory
- Qinghai Pharmaceutical Factory
Highlights of The Bullous Pemphigoid Therapies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Steroid Creams
- Immune Suppressants
- Antibiotics
- By Application:
- Initial Phase
- Active Treatment Phase
- Reducing Phase
- Maintenance Phase
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bullous Pemphigoid Therapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bullous Pemphigoid Therapies are medications that are used to treat bullous pemphigoid. These therapies can help to reduce the inflammation and swelling that is associated with this condition.
Some of the major companies in the bullous pemphigoid therapies market are Regeneron Pharmaceuticals, Sanofi, Pfizer, SUANFARMA, Tecoland Corporation, Century Pharmaceuticals, Akari Therapeutics, Immune Pharmaceuticals, Innate Pharma, AstraZeneca, Grifols, Aptalis, Medicis Pharmaceutical Corporation, Shaanxi Xiyue Pharmaceutical, Kunming Zhenhua Pharmaceutical Factory, Qinghai Pharmaceutical Factory.
The bullous pemphigoid therapies market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bullous Pemphigoid Therapies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bullous Pemphigoid Therapies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bullous Pemphigoid Therapies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bullous Pemphigoid Therapies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bullous Pemphigoid Therapies Market Size & Forecast, 2020-2028
4.5.1 Bullous Pemphigoid Therapies Market Size and Y-o-Y Growth
4.5.2 Bullous Pemphigoid Therapies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Steroid Creams
5.2.2 Immune Suppressants
5.2.3 Antibiotics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Initial Phase
6.2.2 Active Treatment Phase
6.2.3 Reducing Phase
6.2.4 Maintenance Phase
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bullous Pemphigoid Therapies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bullous Pemphigoid Therapies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Steroid Creams
9.6.2 Immune Suppressants
9.6.3 Antibiotics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Initial Phase
9.10.2 Active Treatment Phase
9.10.3 Reducing Phase
9.10.4 Maintenance Phase
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Steroid Creams
10.6.2 Immune Suppressants
10.6.3 Antibiotics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Initial Phase
10.10.2 Active Treatment Phase
10.10.3 Reducing Phase
10.10.4 Maintenance Phase
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Steroid Creams
11.6.2 Immune Suppressants
11.6.3 Antibiotics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Initial Phase
11.10.2 Active Treatment Phase
11.10.3 Reducing Phase
11.10.4 Maintenance Phase
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Steroid Creams
12.6.2 Immune Suppressants
12.6.3 Antibiotics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Initial Phase
12.10.2 Active Treatment Phase
12.10.3 Reducing Phase
12.10.4 Maintenance Phase
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Steroid Creams
13.6.2 Immune Suppressants
13.6.3 Antibiotics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Initial Phase
13.10.2 Active Treatment Phase
13.10.3 Reducing Phase
13.10.4 Maintenance Phase
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bullous Pemphigoid Therapies Market: Competitive Dashboard
14.2 Global Bullous Pemphigoid Therapies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Regeneron Pharmaceuticals
14.3.2 Sanofi
14.3.3 Pfizer
14.3.4 SUANFARMA
14.3.5 Tecoland Corporation
14.3.6 Century Pharmaceuticals
14.3.7 Akari Therapeutics
14.3.8 Immune Pharmaceuticals
14.3.9 Innate Pharma
14.3.10 AstraZeneca
14.3.11 Grifols
14.3.12 Aptalis
14.3.13 Medicis Pharmaceutical Corporation
14.3.14 Shaanxi Xiyue Pharmaceutical
14.3.15 Kunming Zhenhua Pharmaceutical Factory
14.3.16 Qinghai Pharmaceutical Factory
